Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 23Pancreatic Neoplasms 10Colonic Neoplasms 8Stomach Neoplasms 7Esophageal Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urothelial Carcinoma of the Bladder 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1

Interventions

Cisplatin 5Gemcitabine 4Oxaliplatin 2Irinotecan 2Fluorouracil 2Capecitabine 2Bevacizumab 2zanidatamab 1toripalimab 1pembrolizumab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1fludarabine 1envafolimab 1encorafenib 1durvalumab 1binimetinib 1Trastuzumab 1Pemetrexed 1Nivolumab 1Folfox protocol 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Actigraphy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Fluorouracil × 30 days × Clear all
NCT07606599 2026-05-26

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
398 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07582315 2026-05-22

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
538 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡